Jacqueline Wang

555 total citations
20 papers, 279 citations indexed

About

Jacqueline Wang is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Jacqueline Wang has authored 20 papers receiving a total of 279 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 4 papers in Molecular Biology. Recurrent topics in Jacqueline Wang's work include Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Jacqueline Wang is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Jacqueline Wang collaborates with scholars based in United States, China and Hong Kong. Jacqueline Wang's co-authors include Jill S. Barnholtz‐Sloan, Carol Kruchko, Yucai Wang, Quinn T. Ostrom, James R. Connor, Kristin Waite, Michael E. Berens, Gino Cioffi, Justin D. Lathia and Joshua B. Rubin and has published in prestigious journals such as Blood, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Jacqueline Wang

16 papers receiving 277 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jacqueline Wang United States 9 125 81 46 42 37 20 279
Sara Nunnery United States 8 115 0.9× 158 2.0× 83 1.8× 47 1.1× 53 1.4× 15 352
Thomas Gwise United States 10 96 0.8× 56 0.7× 37 0.8× 76 1.8× 56 1.5× 24 316
Michelle Purdom United States 7 129 1.0× 107 1.3× 75 1.6× 29 0.7× 40 1.1× 13 293
Junshan Qiu United States 9 124 1.0× 42 0.5× 48 1.0× 76 1.8× 23 0.6× 22 422
Sreekanth Reddy United States 6 178 1.4× 72 0.9× 96 2.1× 47 1.1× 28 0.8× 11 289
Pierre‐Marie Morice France 7 243 1.9× 97 1.2× 39 0.8× 35 0.8× 44 1.2× 21 382
Αngeliki Andrikopoulou Greece 13 220 1.8× 158 2.0× 89 1.9× 41 1.0× 78 2.1× 41 438
Liviawati Sutjandra United States 7 172 1.4× 102 1.3× 41 0.9× 45 1.1× 17 0.5× 9 330
Kyung‐Hun Lee South Korea 11 205 1.6× 143 1.8× 73 1.6× 22 0.5× 58 1.6× 20 360
Susan Doyle-Lindrud United States 10 92 0.7× 89 1.1× 112 2.4× 33 0.8× 50 1.4× 24 310

Countries citing papers authored by Jacqueline Wang

Since Specialization
Citations

This map shows the geographic impact of Jacqueline Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacqueline Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacqueline Wang more than expected).

Fields of papers citing papers by Jacqueline Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacqueline Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacqueline Wang. The network helps show where Jacqueline Wang may publish in the future.

Co-authorship network of co-authors of Jacqueline Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Jacqueline Wang. A scholar is included among the top collaborators of Jacqueline Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacqueline Wang. Jacqueline Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chan, Nancy, Dirk F. Moore, Kari B. Wisinski, et al.. (2025). Abstract P2-07-21: A phase II study of pembrolizumab plus fulvestrant in ER positive, HER2 negative advanced/metastatic breast cancer patients. Clinical Cancer Research. 31(12_Supplement). P2–7.
2.
Wang, Jacqueline, Jihao Zhou, Han W. Tun, et al.. (2024). Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study. Blood. 144(Supplement 1). 1637–1637.
3.
Feng, Xu, Ke Wang, Chengjun Zhu, et al.. (2024). Tumor-derived extracellular vesicles as a biomarker for breast cancer diagnosis and metastasis monitoring. iScience. 27(4). 109506–109506. 8 indexed citations
4.
Zhu, Chengjun, Peiliang Shen, Jacqueline Wang, et al.. (2024). Hypoxia stimulates CTC-platelet cluster formation to promote breast cancer metastasis. iScience. 27(5). 109547–109547. 6 indexed citations
5.
Wang, Jacqueline & Yucai Wang. (2024). Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Expert Review of Hematology. 17(10). 651–659. 1 indexed citations
6.
Wang, Jacqueline. (2023). Review of EU Maritime Transport Greenhouse Gas Emissions Reduction Policies: Better Prospects for Policy Makers in China?. International Journal of Frontiers in Sociology. 5(9). 1 indexed citations
7.
Wang, Jacqueline, Jihao Zhou, Steven R. Hwang, et al.. (2023). A National Cancer Database Study of Survival Trends in Patients with Mantle Cell Lymphoma Stratified By Age Group. Blood. 142(Supplement 1). 1663–1663. 1 indexed citations
8.
Varma, Gaurav, Jacqueline Wang, & Catherine Diefenbach. (2022). Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma. Expert Review of Anticancer Therapy. 22(8). 795–803. 1 indexed citations
9.
Kommalapati, Anuhya, Allison M. Bock, Jacqueline Wang, et al.. (2021). Influence of Treatment Facility Type and Annual Patient Volume on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis. Blood. 138(Supplement 1). 1348–1348.
10.
Yang, Fang, Jacqueline Wang, Yucai Wang, Baorui Liu, & Julian R. Molina. (2021). Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers. 14(1). 109–109. 39 indexed citations
11.
Cioffi, Gino, Jacqueline Wang, Kristin Waite, et al.. (2020). Sex Differences in Cancer Incidence and Survival: A Pan-Cancer Analysis. Cancer Epidemiology Biomarkers & Prevention. 29(7). 1389–1397. 113 indexed citations
12.
Cheng, Louis T. W., et al.. (2020). Does Supplier Concentration Matter to Investors During the COV1D-19 Crisis: Evidence from China?. SSRN Electronic Journal. 3 indexed citations
13.
Ascha, Mustafa, Jacqueline Wang, Priya Kumthekar, et al.. (2019). Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases. Scientific Reports. 9(1). 17792–17792. 16 indexed citations
14.
Nath, Aritro, Jacqueline Wang, & R. Stephanie Huang. (2017). Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia. Molecular Diagnosis & Therapy. 21(6). 621–631. 16 indexed citations
15.
Yan, Xiang, Li Wang, Ran Zhang, et al.. (2017). Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. OncoImmunology. 7(1). e1376156–e1376156. 16 indexed citations
16.
Wang, Yucai, Fang Yang, Yan Shen, et al.. (2015). Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. JNCI Journal of the National Cancer Institute. 108(3). 32 indexed citations
17.
Geeleher, Paul, Andrey Loboda, Bonnie LaCroix, et al.. (2015). Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. JNCI Journal of the National Cancer Institute. 107(11). djv247–djv247. 14 indexed citations
18.
Geeleher, Paul, et al.. (2015). Abstract B1-01: Whole genome expression based drug repurposing. Cancer Research. 75(22_Supplement_2). B1–1.
19.
20.
Yu, Wayne, et al.. (2008). The Predictive Power of Implied Volatility of Options Traded OTC and on Exchanges. SSRN Electronic Journal. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sara Nunnery Breakdown of academic impact, for papers by Thomas Gwise Breakdown of academic impact, for papers by Michelle Purdom Breakdown of academic impact, for papers by Junshan Qiu Breakdown of academic impact, for papers by Sreekanth Reddy Breakdown of academic impact, for papers by Pierre‐Marie Morice Breakdown of academic impact, for papers by Αngeliki Andrikopoulou Breakdown of academic impact, for papers by Liviawati Sutjandra Breakdown of academic impact, for papers by Kyung‐Hun Lee Breakdown of academic impact, for papers by Susan Doyle-Lindrud
Rankless by CCL
2026